Literature DB >> 9365996

Neuroleptic intolerance.

T E Hansen1, D E Casey, W F Hoffman.   

Abstract

This article reviews antipsychotic medication side effects, especially those that require the physician to discontinue or the patient to be noncompliant with otherwise useful medication. They include such common problems as extrapyramidal syndromes (dystonia, akathisia, drug-induced Parkinsonism, tardive dyskinesia), sedation, weight gain, and sexual dysfunction, as well as less frequent concerns, such as seizures, neuroleptic malignant syndrome, agranulocytosis, torsade de pointes, hepatitis, and dermatological and ophthalmological syndrome. The adverse events associated with some of the new antipsychotic drugs are included. Available information about individual susceptibility to side effects is addressed by syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365996     DOI: 10.1093/schbul/23.4.567

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

1.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

Review 2.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 3.  Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.

Authors:  James J Gugger
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

4.  Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital.

Authors:  Ihechiluru G Anozie; Bawo O James; Joyce O Omoaregba; Sunday O Oriji; Paul O Erohubie; Anthony C Enebe
Journal:  S Afr J Psychiatr       Date:  2022-04-29       Impact factor: 1.242

5.  Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

Authors:  Ana Alkelai; Lior Greenbaum; Amihai Rigbi; Kyra Kanyas; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

6.  Alterations of liver function test in patients treated with antipsychotics.

Authors:  M Teresa Garcia-Unzueta; Andres Herran; Deirdre Sierra-Biddle; J Antonio Amado; J Luis Vázquez-Barquero; Concepción Alvarez
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

Review 7.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

8.  Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.

Authors:  Xiaoning He; Jing Wu; Yawen Jiang; Li Liu; Wenyu Ye; Haibo Xue; William Montgomery
Journal:  BMC Health Serv Res       Date:  2015-04-09       Impact factor: 2.655

9.  Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.

Authors:  Marc Cantillon; Robert Ings; Laxminarayan Bhat
Journal:  Clin Transl Sci       Date:  2018-04-10       Impact factor: 4.689

10.  A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.

Authors:  Marc Cantillon; Robert Ings; Arul Prakash; Laxminarayan Bhat
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-10       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.